Q-omics provides the consensus-scored ILF2P2 profile across patient tissues and cancer cell-line models. ILF2P2 expression is associated with patient survival in 11 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, ILF2P2 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, ILF2P2 RNA expression shows 9,182 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight THCA, BRCA, and GBM as cancer lineages where ILF2P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ILF2P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ILF2P2 survival associations across molecular data types. ILF2P2 RNA expression shows survival associations in the most cancer types (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ILF2P2 RNA expression–survival associations across cancer types. High ILF2P2 expression shows unfavorable associations in THCA, KIRP, MESO and HNSC, but favorable associations in SKCM and UCS. The THCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for ILF2P2 RNA expression.
This table summarizes ILF2P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for ILF2P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ILF2P2 shows lower tumor expression in KICH and THCA and higher tumor expression in BRCA, COAD and KIRC. The BRCA box plot shows higher ILF2P2 RNA expression in tumor versus normal tissue (log2 FC = +0.009, t-test p = .041).
This table shows molecular features associated with ILF2P2 in patient tissues and cancer cell lines. In patient samples, ILF2P2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set.
